US Patent Issued to ProMab Biotechnologies, Forevertek Biotechnology on Feb. 10 for "Humanized CD37 and bi-specific CD19-humanized CD37 CAR-T cells" (California Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,545,742, issued on Feb. 10, was assigned to ProMab Biotechnologies Inc. (Richmond, Calif.) and Forevertek Biotechnology Co. Ltd (Changsha, China).

"Humanized CD37 and bi-specific CD19-humanized CD37 CAR-T cells" was invented by Lijun Wu (Berkeley, Calif.) and Vita Golubovskaya (Pinole, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is directed to humanized CD37-CAR comprising humanized CD37 scFv of the present invention. The present invention is also directed to a bispecific CD19-humanized CD37 CAR, comprising: (i) CD19 VL, (ii) Humanized CD37 ScFv, (iii) CD19 VH, (iv) a transmembrane domain, (v) at least one co-stimulatory ...